JarowJP, LaVangeL, WoodcockJ. Multidimensional evidence generation and FDA regulatory decision making: defining and using “real-world” data. JAMA, 2017; 318: 703–704.
2.
BjornstadP, DonaghueKC, MaahsDM. Macrovascular disease and risk factors in youth with type 1 diabetes: time to be more attentive to treatment?. Lancet Diabetes Endocrinol, 2018; 6: 809–820.
3.
RawshaniA, SattarN, FranzénS, et al.Excess mortality and cardiovascular disease in type 1 diabetes in relation to age at onset: a nationwide study of 27,195 young adults with diabetes. Lancet, 2018; 392: 477–486.
4.
BasinaM, MaahsDM. Age at type 1 diabetes onset: a new cardiovascular disease risk factor and call for focused treatment?. Lancet, 2018; 392: 453–454.
5.
SherrJL, HermannJM, CampbellF, et al; T1D Exchange Clinic Network, the DPV Initiative, and the National Paediatric Diabetes Audit and the Royal College of Paediatrics and Child Health registries. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia, 2016; 59: 87–91.
6.
SzypowskaA, SchwandtA, SvenssonJ, et al; SWEET Study Group. Insulin pump therapy in children with type 1 diabetes: analysis of data from the SWEET registry. Pediatr Diabetes, 2016; 17(suppl 23): 38–45.
7.
BlackmanSM, RaghinaruD, AdiS, et al.Insulin pump use in young children in the T1D Exchange clinic registry is associated with lower hemoglobin A1c levels than injection therapy. Pediatr Diabetes, 2014; 15: 564–572.
8.
BrorssonAL, ViklundG, ÖrtqvistE, Lindholm OlinderA. Does treatment with an insulin pump improve glycaemic control in children and adolescents with type 1 diabetes? a retrospective case-control study. Pediatr Diabetes, 2015; 16: 546–553.
9.
HanasR, LindgrenF, LindbladB. A 2-yr national population study of pediatric ketoacidosis in Sweden: predisposing conditions and insulin pump use. Pediatr Diabetes, 2009; 10: 33–37.
10.
McKinlayCJD, AlsweilerJM, AnsticeNS, et al.Children with hypoglycemia and their later development (CHYLD) study team. “Association of neonatal glycemia with neurodevelopmental outcomes at 4.5 years.”. JAMA Pediatr, 2017; 171: 972–983.
11.
MillerKM, FosterNC, BeckRW, et al; T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the US: updated data from the T1D Exchange Clinic registry. Diabetes Care, 2015; 38: 971–978.
12.
BorusJS, LaffelL. Adherence challenges in the management of type 1 diabetes in adolescents: prevention and intervention. Curr Opin Pediatr, 2010; 22: 405–411.
13.
EdgeJ, AceriniC, CampbellF, et al.An alternative sensor-based method for glucose monitoring in children and young people with diabetes. Arch Dis Child, 2017; 102: 543–549.
14.
BuckinghamBA, RaghinaruD, CameronF, et al.; In Home Closed Loop Study Group. Predictive low-glucose insulin suspension reduces duration of nocturnal hypoglycemia in children without increasing ketosis. Diabetes Care, 2015; 38: 1197–204.
15.
BergenstalRM, GargS, WeinzimerSA, et al.Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA, 2016 4; 316: 1407–1408.
16.
RiddellMC, GallenIW, SmartCE, et al.Exercise management in type 1 diabetes: a consensus statement. Lancet Diabetes Endocrinol, 2017; 5: 377–390.
17.
AdolfssonP, RiddellMC, TaplinCE, et al.ISPAD Clinical Practice Consensus Guidelines 2018: exercise in children and adolescents with diabetes. Pediatr Diabetes, 2018; 19 (Suppl 27): 205–226.
18.
MesserLH, ForlenzaGP, WadwaRP, et al.The dawn of automated insulin delivery: A new clinical framework to conceptualize insulin administration. Pediatr Diabetes, 2018; 19: 14–17.
19.
SherrJL, TauschmanM, BattelinoT, et al.ISPAD clinical practice consensus guidelines 2018 Diabetes Technologies. Pediatr Diabetes, 2018; 19Suppl 27: 302–325.
20.
BohnB, HerbstA, PfeiferM, et al.; DPV Initiative. Impact of physical activity on glycemic control and prevalence of cardiovascular risk factors in adults with type 1 diabetes: a cross-sectional multicenter study of 18,028 patients. Diabetes Care, 2015; 38: 1536–1543.
21.
MetcalfKM, SinghviA, TsalikianE, et al.Effects of moderate-to-vigorous intensity physical activity on overnight and next-day hypoglycemia in active adolescents with type 1 diabetes. Diabetes Care, 2014; 37: 1272–1278.
de BoerIH, GaoX, ClearyPA, et al.Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT/EDIC Study. Clin J Am Soc Nephrol, 2016; 11: 1969–1977.
24.
HolmanRR, PaulSK, BethelMA, MatthewsDR, NeilHAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008; 359: 1577–1589.
25.
ZoungasS, ChalmersJ, NealB, et al.Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med, 2014; 371: 1392–406.
26.
MathieuC, ZinmanB, HemmingssonJU, et al.; ADJUNCT ONE Investigators. Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: the ADJUNCT ONE treat-to-target randomized trial. Diabetes Care, 2016; 39: 1702–1710.
27.
KuhadiyaND, GhanimH, MehtaA, et al.Dapagliflozin as additional treatment to liraglutide and insulin in patients with type 1 diabetes. J Clin Endocrinol Metab, 2016; 101: 3506–3515.
28.
InzucchiSE, MaggsDG, SpollettGR, et al.Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med, 1998; 338: 867–872.
29.
AbbasiF, ChuJW, McLaughlinT, LamendolaC, LearyET, ReavenGM. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism, 2004; 53: 159–164.
30.
LibmanIM, MillerKM, DiMeglioLA, et al.; T1D Exchange Clinic Network Metformin RCT Study Group. Effect of Metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA, 2015; 1; 314: 2241–2250.
31.
Al KhalifahRA, AlnhdiA, AlgharH, AlanaziM, FlorezID. The effect of adding metformin to insulin therapy for type 1 diabetes mellitus children: a systematic review and meta-analysis. Pediatr Diabetes, 2017; 18: 664–673.
32.
ShahAS, DabeleaD, FinoNF, et al.Predictors of increased carotid intima-media thickness in youthwith type 1 diabetes: the SEARCH CVD study. Diabetes Care, 2016; 39: 418–425.
33.
NathanDM, LachinJ, ClearyP, et al.; Diabetes Control and Complications Trial Epidemiology of Diabetes Interventions and Complications Research Group. Intensive diabetes therapy and carotid intima media thickness in type 1 diabetes mellitus. N Engl J Med, 2003; 348: 2294–2303.
34.
PetittiDB, KlingensmithGJ, BellRA, et al.Glycemic control in youth with diabetes: the SEARCH for Diabetes in Youth study. J Pediatr, 2009; 155: 668–672.
35.
NambamB, SilversteinJ, ChengP, et al.A cross-sectional view of the current state of treatment of youth with type 2 diabetes in the enrollment data from the Pediatric Diabetes Consortium Type 2 Diabetes Registry. Pediatr Diabetes, 2017; 18: 222–229.
36.
InselRA, DunneJL, AtkinsonMA, et al.Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care, 2015; 38: 1964–1974.
